Rankings
▼
Calendar
DNLI
Denali Therapeutics Inc.
$3B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
-100.0% YoY
Gross Profit
$0
Operating Income
-$133M
Net Income
-$119M
EPS (Diluted)
$-0.86
QoQ Revenue Growth
-100.0%
Cash Flow
Operating Cash Flow
-$99M
Free Cash Flow
-$101M
Stock-Based Comp.
$26M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$123M
Stockholders' Equity
$1.0B
Cash & Equivalents
$127M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$10M
-100.0%
Gross Profit
$0
$10M
-100.0%
Operating Income
-$133M
-$105M
-25.8%
Net Income
-$119M
-$99M
-21.1%
← FY 2023
All Quarters
Q1 2024 →
DNLI Q4 2023 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena